Konza Technopolis to Host Kenya's First Biopharma Life Sciences Park
Kenya has moved closer to having its first dedicated pharmaceutical and life sciences manufacturing hub. Apifa Biotech has secured grant funding from Swedfund International to pay for preparatory studies on a proposed Biopharma Life Sciences Park at Konza Technopolis.
Swedfund is Sweden's development finance institution. According to Tuko, the deal was announced on November 12. It is being presented as an important step towards reducing Kenya's dependence on imported medicines and building up local healthcare manufacturing.
A public-private partnership
The project is a public-private partnership between Apifa Biotech and the Technopolis Development Authority, the state agency overseeing Konza. Tuko reports that the National Treasury approved the project in April 2026, allowing it to move into the development phase.
Under the arrangement, Apifa Biotech will design, develop and finance the park. It is intended to bring pharmaceutical manufacturers, researchers, investors and technology firms together in one shared environment.
Swedfund's grant will cover the technical and commercial assessments needed to show whether the project is viable. These studies are also expected to lay the groundwork for attracting long-term private investment.
JLL and IQVIA to run feasibility study
The feasibility study will be carried out by a consortium of two firms:
- Jones Lang LaSalle (JLL), a global real estate and investment advisory firm
- IQVIA, a healthcare research and analytics company
The consortium brings expertise in life sciences strategy, infrastructure development and investment planning, according to Tuko.
Its findings are expected to shape the park's technical requirements, commercial structure and roadmap for implementation. The study is now under way.
Konza as a pharmaceutical destination
Technopolis Development Authority Chief Executive Officer John Paul Okwiri said the park would turn Konza into a destination for pharmaceutical manufacturing and biotechnology innovation.
Okwiri also said the project shows how public-private partnerships can bring together the money and technical skills needed to deliver large infrastructure projects.
Apifa Biotech Board Chairman Dr Gerald Macharia and Chief Executive Officer Dr Keter attended the signing ceremony. Their presence reaffirmed the company's commitment to the project.
Part of a wider push for local production
The initiative supports the African Union's target of meeting 60 per cent of Africa's health product needs through local production by 2040.
It also fits Kenya's own policy goal of sourcing at least half of its essential health products from within the country.
Like many African countries, Kenya relies heavily on imports for medicines and other health products. This leaves supply chains exposed to disruptions abroad. Building local manufacturing capacity has therefore become a growing priority for governments and development partners across the continent.
What happens next
The next milestone is the completion of the JLL-IQVIA feasibility study. Its findings will determine how the park is structured and delivered.
No timeline for construction or total project cost was given in the announcement. The studies funded by Swedfund are meant to establish whether the venture can draw the long-term private capital it will need to go ahead.
This story was prepared by the Hamasta Newsdesk with AI assistance, based on reporting by Tuko. Read the original report. Photo: Tuko.
More in Business
See all
Anthropic heads for record US share sale as debate over AI bubble intensifies

Stanbic locks Vodacom out of Sh9.1bn Safaricom dividends after court ruling

Tunisia's olive oil exports surge nearly 50% after record harvest

StanChart, pension trustees ordered to pay Sh773m legal costs to 629 retirees

Kenya to switch on South Lokichar oil rig as crude trade name list narrows to four







Global Community Remarks
0